XOMA (NASDAQ:XOMA) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of XOMA (NASDAQ:XOMA – Get Rating) from a hold rating to a sell rating in a research report report published on Monday morning.

Separately, HC Wainwright restated a buy rating and set a $69.00 target price on shares of XOMA in a research report on Friday.

XOMA Stock Down 2.9 %

NASDAQ:XOMA opened at $21.03 on Monday. XOMA has a 52 week low of $15.68 and a 52 week high of $32.08. The stock has a market capitalization of $241.00 million, a PE ratio of -10.68 and a beta of 0.89. The stock’s 50-day moving average price is $21.15 and its 200-day moving average price is $19.20.

Insider Buying and Selling

In other news, Director Bvf Partners L. P/Il acquired 19,000 shares of the stock in a transaction that occurred on Thursday, January 5th. The shares were bought at an average cost of $18.39 per share, for a total transaction of $349,410.00. Following the acquisition, the director now owns 1,788,168 shares in the company, valued at approximately $32,884,409.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On XOMA

Several institutional investors have recently bought and sold shares of the company. Natixis acquired a new stake in XOMA in the 4th quarter worth about $66,000. Millennium Management LLC boosted its holdings in XOMA by 86.8% in the 4th quarter. Millennium Management LLC now owns 55,305 shares of the biotechnology company’s stock worth $1,018,000 after buying an additional 25,697 shares during the last quarter. Knott David M Jr acquired a new position in shares of XOMA during the 4th quarter worth approximately $210,000. Bank of America Corp DE boosted its holdings in shares of XOMA by 40.7% during the 4th quarter. Bank of America Corp DE now owns 2,380 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 689 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of XOMA by 814.4% during the 4th quarter. Citigroup Inc. now owns 17,063 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 15,197 shares during the last quarter. 54.89% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

(Get Rating)

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.